Skip to content

Vicriviroc effective in treatment-experienced patients, but malignancy questions remain unanswered

New data shed light on poor outcome in SMART study

Merck launches expanded access programme for integrase inhibitor

Oral solution of tipranavir/ritonavir shows promise for treatment-experienced kids

Researchers launch hunt for people who control HIV without drugs

Anal cancer increases in French HIV cohort, despite use of antiretroviral therapy

Ranbaxy presents bioequivalence data on two paediatric fixed dose triple combination tablets

Abacavir/3TC backbone proves most durable for children over five years

Mixed results on ELISPOT TB testing in resource-limited settings